What is the appropriate starting dose of chlorpromazine (Thorazine) for an adult?

Starting Dose of Chlorpromazine (Thorazine)

For adults with psychotic disorders, start chlorpromazine at 25 mg intramuscularly for acute symptoms in hospitalized patients, or begin oral therapy at lower doses and titrate gradually based on severity and patient tolerance. 1

Dosing by Clinical Context

Hospitalized Patients with Acute Psychosis

For acute schizophrenic or manic states, the FDA-approved starting regimen is:

• IM: 25 mg initially
• If necessary, give an additional 25-50 mg injection after 1 hour
• Gradually increase subsequent IM doses over several days, up to 400 mg every 4-6 hours in exceptionally severe cases
• Most patients become quiet and cooperative within 24-48 hours, at which point switch to oral dosing 1

Outpatient or Less Acute Settings

The FDA label emphasizes adjusting dosage to the individual and severity of condition, with the critical principle being to increase dosage gradually until symptoms are controlled 1. The label specifically notes that dosage should be increased more gradually in debilitated or emaciated patients and elderly patients 1.

Therapeutic Dose Range Context

While the FDA label doesn't specify an exact starting oral dose for all situations, important context comes from treatment-resistant schizophrenia guidelines: a therapeutic dose is considered equivalent to at least 600 mg chlorpromazine daily when assessing adequate treatment trials 2. However, this represents a target therapeutic dose, not a starting dose.

Research evidence suggests that moderate doses (300-600 mg chlorpromazine equivalent daily) are adequate for most psychotic patients, and there is failure to support routine use of higher doses 3. A Cochrane review found that low doses (≤400 mg/day) showed no clear disadvantage compared to medium doses (401-800 mg/day) for efficacy, but medium and high doses caused significantly more extrapyramidal symptoms 4.

Practical Dosing Algorithm

Start low and titrate up:

1. Acute hospitalized patients: Begin with 25 mg IM, repeat as needed per FDA guidance above
2. Less acute/outpatient settings: Start with lower oral doses (the FDA label references 25-50 mg tid as a typical post-acute regimen) 1
3. Titrate gradually over days to weeks until symptom control
4. Target range: Aim for 300-600 mg/day equivalent for most patients
5. Maximum improvement may not be seen for weeks or even months 1

Critical Safety Considerations

• Elderly patients: Use lower range doses; they are more susceptible to hypotension and neuromuscular reactions. Monitor closely and increase more gradually 1
• Debilitated/emaciated patients: Increase dosage more gradually 1
• Cardiovascular, liver, or renal disease: Administer cautiously 1
• Monitor for hypotension before increasing parenteral dosage 1
• Extrapyramidal symptoms increase significantly with higher doses (moderate-quality evidence) 4

Common Pitfalls to Avoid

1. Starting too high: The historical trend toward dose escalation lacks evidence support 3. Starting with excessive doses increases side effects without improving efficacy
2. Increasing too rapidly: The FDA label repeatedly emphasizes gradual titration, particularly in vulnerable populations 1
3. Assuming all patients need high doses: Most patients respond adequately to moderate doses (300-600 mg/day equivalent) 3
4. Ignoring individual variation: While rare, some patients may require higher doses due to idiosyncratic pharmacokinetics 3

The 2025 INTEGRATE guidelines recommend giving the first antipsychotic at a therapeutic dose for at least 4 weeks before assessing response 5, but this refers to maintaining an adequate therapeutic dose once reached, not the starting dose itself.